EXTENDED RELEASE AMPHETAMINE TABLETS
An oral amphetamine extended release solid dose is described. The compositions contain a combination of an uncoated amphetamine-cation exchange resin complex, a barrier coated amphetamine-cation exchange resin complex-matrix, and an uncomplexed amphetamine, wherein one or more of these components contains blends of different forms of amphetamines. Either the modified release coated and/or the uncoated amphetamine-cation exchange resin complex may have two forms of amphetamine in a complex with a single cation exchange resin. Following administration of a single dose of the composition, a therapeutically effective amount of amphetamine is reached by about one hour and the composition provides at least a thirteen hour effect post-dose.
1 . (canceled)
2 . A once-daily amphetamine tablet, wherein the tablet provides an immediate release and a modified release profile for d-amphetamine and for 1-amphetamine through 13 hours, and wherein the tablet further comprises:
(A) a modified release amphetamine component which comprises at least one modified release barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) (d,l)-amphetamine and d-amphetamine bound to the same cation exchange resin or each bound to a different cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating which provides a modified release to the amphetamines, wherein the barrier coating comprises polyvinyl acetate and a plasticizer; and
wherein the ratio of d-amphetamine to l-amphetamine is about 3.2 to about 1;
(B) immediate release amphetamine components which comprise greater than 60% w/w of the total amphetamines based on the total weight of free amphetamine base in the tablet, and wherein the immediate release amphetamine components are (i), (ii) and (iii):
(i) an immediate release amphetamine-cation exchange resin complex in an optional matrix, wherein the amphetamine-cation exchange resin complex-optional matrix comprises (d,l)-amphetamine and d-amphetamine both bound to the same cation exchange resin; and
(ii) an amphetamine aspartate; and
(iii) a dextroamphetamine sulfate.
3 . The tablet of claim 2 , wherein the tablet is scored and chewable.
4 . The tablet of claim 2 , wherein the tablet comprises a dose of 5 mg amphetamine, as calculated based on the amount of free amphetamine base.
5 . The tablet according to claim 2 , wherein the tablet comprises a dose of 20 mg amphetamine, as calculated based on the amount of free amphetamine base.
6 . A method of treating attention deficit hyperactivity disorder (ADHD) in a patient aged 6 to 12 comprising providing a once-daily amphetamine tablet to an ADHD patient in the morning, wherein the tablet provides an immediate release and a modified release profile through 13 hours, and wherein the tablet further comprises:
(A) a modified release amphetamine component which comprises at least one modified release barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) (d,l)-amphetamine and d-amphetamine bound to the same cation exchange resin or each bound to a different cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating which provides a modified release to the amphetamines, wherein the barrier coating comprises polyvinyl acetate and a plasticizer; and
wherein the ratio of d-amphetamine to l-amphetamine is about 3.2 to about 1;
(B) immediate release amphetamine components which comprise greater than 60% w/w of the total amphetamines based on the total weight of free amphetamine base in the tablet, and wherein the immediate release amphetamine components are (i), (ii) and (iii):
(i) an immediate release amphetamine-cation exchange resin complex in an optional matrix, wherein the amphetamine-cation exchange resin complex-optional matrix comprises (d,l)-amphetamine and d-amphetamine both bound to the same cation exchange resin; and
(ii) an amphetamine aspartate; and
(iii) a dextroamphetamine sulfate.
7 . The method of claim 6 , wherein the therapeutic effect in a patient under 18 years old is determined using a SKAMP assessment.
8 . The method of claim 6 , wherein the therapeutic effect in a patient aged 6-12 years old is determined using a SKAMP assessment.
9 . An extended release amphetamine solid composition, wherein the composition provides an immediate release and a therapeutic effect through about 13-hours, wherein the composition lacks a pH-dependent coating which provides delayed release to an amphetamine component, and wherein the composition further comprises:
(A) about 10% w/w to 30% w/w of a modified release amphetamine component which comprises at least one modified release barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) (d,l)- and (d)-amphetamines bound to the same cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating comprising a pH-independent, water-insoluble polymer and a plasticizer, which barrier coating provides a modified release to the amphetamines;
(B) immediate release amphetamine components which comprise greater than 70% w/w of the total amphetamines based on the total weight of free amphetamine base in the composition, and wherein the immediate release amphetamine components are (i), (ii) and (iii):
(i) at least one amphetamine-cation exchange resin complex, wherein the amphetamine-cation exchange resin complex comprises at least a d-amphetamine and an l-amphetamine both bound to the same cation exchange resin or each bound to different cation exchange resins, wherein the d-amphetamine and the 1-amphetamine are provided by d-amphetamine and at least one of (d, 1)-amphetamine or 1-amphetamine;
(ii) an immediate release amphetamine aspartate; and
(iii) an immediate release dextroamphetamine sulfate.
10 . The composition of claim 9 , wherein the composition is an orally dissolving or dispersible tablet.
11 . The composition of claim 9 , wherein the composition is a chewable tablet.
12 . The composition of claim 9 , wherein the composition is a scored tablet.
13 . The composition of claim 9 , wherein the composition comprises a dose of 5 mg to 20 mg amphetamine, as calculated based on the amount of free amphetamine base.
14 . A method of treating attention deficit hyperactivity disorder (ADHD) in a patient aged 6 to 12 comprising providing an extended release amphetamine solid composition to an ADHD patient in the morning, wherein the composition provides an immediate release and a therapeutic effect through about 13-hours post-dosing for d-amphetamine and for l-amphetamine, wherein the composition lacks a pH-dependent coating which provides delayed release to an amphetamine component, and wherein the composition further comprises:
(A) about 10% w/w to 30% w/w of a modified release amphetamine component which comprises at least one modified release barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) (d,l)- and (d)-amphetamines bound to the same cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating comprising a pH-independent, water-insoluble polymer and a plasticizer, which barrier coating provides a modified release to the amphetamines;
(B) immediate release amphetamine components which comprise greater than 70% w/w of the total amphetamines based on the total weight of free amphetamine base in the composition, and wherein the immediate release amphetamine components are (i), (ii) and (iii):
(i) at least one amphetamine-cation exchange resin complex, wherein the amphetamine-cation exchange resin complex comprises at least a d-amphetamine and an l-amphetamine both bound to the same cation exchange resin or each bound to different cation exchange resins, wherein the d-amphetamine and the 1-amphetamine are provided by d-amphetamine and at least one of (d, 1)-amphetamine or 1-amphetamine;
(ii) an immediate release amphetamine aspartate; and
(iii) an immediate release dextroamphetamine sulfate.
15 . The method of claim 14 , wherein the therapeutic effect in a patient under 18 years old is determined using a SKAMP assessment.
16 . The method of claim 14 , wherein the therapeutic effect in a patient aged 6-12 years old is determined using a SKAMP assessment.
17 . A method of treating a central nervous system disorder in a patient, comprising providing a once-daily amphetamine tablet, wherein the tablet provides an immediate release and a modified release profile through 13 hours, and wherein the tablet further comprises:
(A) a modified release amphetamine component which comprises at least one modified release barrier coated amphetamine-cation exchange resin complex-optional matrix which comprises (i) (d,l)-amphetamine and d-amphetamine bound to the same cation exchange resin or each bound to a different cation exchange resin, wherein when the optional matrix is present, the amphetamine-cation exchange resin complex-matrix further comprises a hydrophilic polymer or copolymer or a hydrophobic polymer and (ii) a water-insoluble, water-permeable, pH-independent, barrier coating which provides a modified release to the amphetamines, wherein the barrier coating comprises polyvinyl acetate and a plasticizer; and
wherein the ratio of d-amphetamine to l-amphetamine is about 3.2 to about 1;
(B) immediate release amphetamine components which comprise greater than 60% w/w of the total amphetamines based on the total weight of free amphetamine base in the tablet, and wherein the immediate release amphetamine components are (i), (ii) and (iii):
(i) an immediate release amphetamine-cation exchange resin complex in an optional matrix, wherein the amphetamine-cation exchange resin complex-optional matrix comprises (d,l)-amphetamine and d-amphetamine both bound to the same cation exchange resin; and
(ii) an amphetamine aspartate; and
(iii) a dextroamphetamine sulfate.
18 . The method of claim 17 , wherein the central nervous system disorder is attention deficit hyperactivity disorder (ADHD).